You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Recently a new oral drug is approved for treatment of multiple myeloma. It acts as a selective inhibitor of nuclear expo. Which drug is it ? and explain in detail?
SELINEXOR : - It is an oral selective inhibitor of nuclear expo (SINE) compound. - It works by binding to Nuclear expo protein (Expoin 1) and inhibiting the transpo of several proteins (involved in cancer cell growth) from nucleus to cytoplasm. This results in accumulation of tumor suppressor proteins in the cell nucleus. This will reinitiate and amplifies tumor suppressor function and leads to selective induction of apoptosis in cancer cells. - Used for multiple myeloma and Diffuse large B cell lymphoma. POLATUZUMAB : - Antibody targeting the CD 79 B component of the B cell receptor. - Used for relapsed or refractory diffuse large B cell lymphoma. ZANUBRUTINIB : - It is a Bruton tyrosine kinase inhibitor like ibrutinib - Used for Mantle cell lymphoma. FEDRATINIB : - It is a oral JAK 2 inhibitor - Used for MYELOFIBROSIS.